Insights Archive

Financial Market Tumult Shows The Need For Creative Funding For Life Sciences

Financial Market Tumult Shows The Need For Creative Funding For Life Sciences

The Federal Reserve’s move to raise interest rates to battle inflation – now running at approximately 8% annually – has altered the risk and return for investors, resulting in substantial market volatility. While life sciences companies are in a period of great innovation, they have not been immune to the upheaval in the financial markets and need creative funding alternatives when it comes to raising capital.

Beyond the Four Corners

Beyond the Four Corners

Factors to Consider When Choosing a Lender The four corners of the credit agreement will contain all of the important contractual terms and conditions to which a lender and borrower have agreed to be bound. The language will dictate what is required of each party...

Case Study: Opiant (Royalty)

Case Study: Opiant (Royalty)

Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth due to a differentiated nasal dosing and expanded distribution, not price hikes Opiant is a publicly traded drug...